Scholarlink

<p>Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage degradation and inflammation, driven by pro-inflammatory cytokines such as interleukin-1 beta (IL-1β). Current treatments for OA focus mainly on symptom management, with limited efficacy in targeting the underlying disease mechanisms. In this study, we developed a novel multifunctional drug delivery system (PMES-TO) by functionalizing 3-carboxypropyltriethoxysilane (PMES) with thiazole orange (TO) to enhance the targeting, fluorescence properties, and delivery performance of the OA-targeting drug Pomalidomide (POM). Compound 1 was synthesized as an adjunct to POM, forming the composite system PMES-TO@1@POM. The system was characterized using FT-IR, DSC, UV-Vis, and fluorescence spectroscopy, confirming the successful integration of PMES and TO. PMES-TO@1@POM exhibited high drug loading efficiency, stability at physiological pH, and pH-responsive drug release, with up to 79% release within 12 hours at pH 5.8. In an IL-1β-induced OA model, the combination of compound 1 and POM significantly reduced the expression of key collagenases compared to POM alone, demonstrating enhanced therapeutic efficacy. The PMES-TO system offers improved drug targeting and efficacy for OA treatment, providing a promising approach for the development of more effective OA therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fluorescent Nanoparticle Drug Delivery System Based on Polymer-Silicon Materials and Its Synergistic Effects in Osteoarthritis

  • 期刊论文

  • 发表日期：

    2025年4月2日

查看全文
  • Yu-Hao Cui,
  • Gang Hou,
  • Jin-Yi Zhu

摘要

Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage degradation and inflammation, driven by pro-inflammatory cytokines such as interleukin-1 beta (IL-1β). Current treatments for OA focus mainly on symptom management, with limited efficacy in targeting the underlying disease mechanisms. In this study, we developed a novel multifunctional drug delivery system (PMES-TO) by functionalizing 3-carboxypropyltriethoxysilane (PMES) with thiazole orange (TO) to enhance the targeting, fluorescence properties, and delivery performance of the OA-targeting drug Pomalidomide (POM). Compound 1 was synthesized as an adjunct to POM, forming the composite system PMES-TO@1@POM. The system was characterized using FT-IR, DSC, UV-Vis, and fluorescence spectroscopy, confirming the successful integration of PMES and TO. PMES-TO@1@POM exhibited high drug loading efficiency, stability at physiological pH, and pH-responsive drug release, with up to 79% release within 12 hours at pH 5.8. In an IL-1β-induced OA model, the combination of compound 1 and POM significantly reduced the expression of key collagenases compared to POM alone, demonstrating enhanced therapeutic efficacy. The PMES-TO system offers improved drug targeting and efficacy for OA treatment, providing a promising approach for the development of more effective OA therapies.